US Pat. No. 10,166,267

MULTI-COMPONENT FORMULATIONS FOR THE TREATMENT OF COGNITIVE DECLINE INCLUDING ALZHEIMER'S DISEASE

1. A multi-component formulation comprising:about 0.01% to about 5% by weight methylsulfonylmethane,
about 5% to about 99% by weight fructose 1,6-diphosphate, and
about 0.01% to about 95% by weight of at least one of an herbal component or a nutritional component comprising curcumin.
US Pat. No. 10,168,321

COMPOSITION COMPRISING UP-CONVERTING PHOSPHORS FOR DETECTING AN ANALYTE

Roche Diabetes Care, Inc....

1. A detector matrix for detecting at least one analyte in a sample comprising (i) at least one enzyme active in the presence of said at least one analyte and (ii) at least one indicator reagent changing at least one optical property dependent on the activity of said enzyme, wherein the indicator reagent is homogenously distributed within said detector matrix, wherein said detector matrix further comprises (iii) UV-emitting up-converting phosphor particles.
US Pat. No. 10,166,273

SYNERGISTIC TUMOR TREATMENT WITH ANTIBODIES TARGETING PD-1, PD-L1 OR CTLA4 AND INTEGRIN-BINDING-FC-FUSION PROTEIN

The Board of Trustees of ...

1. A method for inhibiting growth and/or proliferation of tumor cells in a subject comprising administering to the subject an effective amount of an integrin-binding-Fc fusion protein, wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold; and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain, and an immune checkpoint blocker selected from the group consisting of an antibody or antibody fragment targeting PD-1, an antibody or antibody fragment targeting PD-L1, and an antibody or antibody fragment targeting CTLA4.
US Pat. No. 10,168,322

ELECTRONIC ANALYTE ASSAYING DEVICE

1. A diagnostic device for detecting the presence of an analyte in a fluid sample, the device comprising:a housing configured to receive a lateral flow diagnostic strip, said lateral flow diagnostic strip including:
a receiving end for receiving the fluid sample;
a terminal end opposite said receiving end; and
a capture region located between said receiving end and said terminal end; and a processor configured to, upon receiving the fluid sample:
illuminate the lateral flow diagnostic strip;
measure intensity values of light reflected from the lateral flow diagnostic strip;
obtain, during a first time period, a first series of intensity value pairs, wherein each intensity value pair of the first series of intensity value pairs comprises a measurement signal and a background signal, and wherein the measurement signal and the background signal for each intensity value pair of the first series of intensity value pairs are obtained at substantially the same time;
calculate the intensity difference between the measurement signal and the background signal for each pair of the first series of intensity value pairs to generate a first series of intensity difference values;
generate, at the end of the first time period, a fluid front detection result based at least in part on the first series of intensity difference values, wherein the fluid front detection result indicates whether at least a portion of the first series of intensity difference values correspond to a threshold for identifying a fluid front;
obtain, during a second time period, a second series of intensity value pairs, wherein each intensity value pair of the second series of intensity value pairs comprises a measurement signal and a background signal, and wherein the measurement signal and the background signal for each intensity value pair of the second series of intensity value pairs are obtained at substantially the same time;
calculate the intensity difference between the measurement signal and the background signal for each pair of the second series of intensity value pairs to generate a second series of intensity difference values; and
generate, at the end of the second time period, a message indicating that the analyte is present in the fluid sample based at least in part on:
(i) the fluid front detection result generated with the first series of intensity difference values obtained during the first time period, and
(ii) the second series of intensity difference values obtained during the second time period.
US Pat. No. 10,166,275

ANTIMICROBIAL COMPOSITION COMPRISING PYROGENIC SILICA AND SERRATHIOPEPTIDASE AND USES THEREOF

Willingsford Limited., S...

1. An antimicrobial composition comprising from 90 to 99% by weight a silicious absorbent made of globules of fine hydrated pyrogenic silica and polysilicic acid (SiO2*H2O); and the remainder by weight, comprising 1 to 10% serrathiopeptidase immobilized thereon; wherein said antimicrobial composition is a dry powder.
US Pat. No. 10,166,531

CATALYST FOR SELECTIVELY CATALYTICALLY OXIDIZING HYDROGEN SULFIDE, CATALYST FOR BURNING TAIL-GAS, AND PROCESS FOR DEEPLY CATALYTICALLY OXIDIZING HYDROGEN SULFIDE TO ELEMENT SULFUR

Nan Yang, Zibo, Shandong...

1. A catalyst for selectively catalytically oxidizing hydrogen sulfide, comprising components of a mass percent of: 13-34% of iron trioxide, 60-72% of anatase titanium dioxide and a balance which are auxiliary agents.
US Pat. No. 10,166,276

COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKINS LYMPHOMA

The Trustees of the Unive...

1. A method of inducing an immune response against a B cell lymphoma in a subject, comprising administering a pharmaceutical composition comprising a fusion polypeptide comprising a fragment of a listeriolysin O (LLO) protein and an antigen, wherein said fragment of an LLO protein is chemically conjugated to said antigen, wherein said antigen is a fragment of a B cell receptor (BCR) comprising the idiotype of said BCR, and wherein said fragment of an LLO protein is an N-terminal fragment comprising the amino acid sequence set forth in SEQ ID NO: 25 or an N-terminal LLO-detox fragment comprising the amino acid sequence set forth in SEQ ID NO: 41.
US Pat. No. 10,167,301

PROCESS FOR THE PREPARATION OF BIS(CHLOROMETHYL)DICHLOROSILANE AND BIS(CHLOROMETHYL)(ARYL)CHLOROSILANE

Dow Global Technologies L...

1. A process for the preparation of bis(chloromethyl)dichlorosilane comprising reacting bis(chloromethyl)diarylsilane and one or more chloride compounds in the presence of one or more Lewis acids in an inert solvent and under an inert atmosphere.
US Pat. No. 10,168,325

NON-SPECIFIC REACTION INHIBITOR

LSI MEDIENCE CORPORATION,...

1. A method for inhibiting a non-specific reaction in an immunological measurement, said method comprising:preparing a sample containing an antigen to be measured;
preparing a solution containing a polymer-modified fragment of an antibody specific to a non-specific reaction factor, wherein the polymer is selected from the group consisting of polyethylene glycol, dextran, bovine serum albumin, and polyglutamic acid, the fragment of the antibody is Fab?, and the non-specific reaction factor is selected from the group consisting of IgM, IgG, IgA, IgE, and IgD;
mixing the solution with the sample to react the polymer-modified fragment with the non-specific reaction factor, before an antibody specific to the antigen is reacted with the antigen, and adding the antibody specific to the antigen to the mixture; and
inhibiting a non-specific reaction caused by the non-specific reaction factor.
US Pat. No. 10,168,326

INTERFERENCE-SUPPRESSED IMMUNOASSAY TO DETECT ANTI-DRUG ANTIBODIES IN SERUM SAMPLES

F. HOFFMANN-LA ROCHE INC....

1. An interference-suppressed immunoassay for the detection of anti-drug antibodies against a drug antibody for the treatment of rheumatoid arthritis, juvenile arthritis, or osteoarthritis, said method comprising:(a) incubating a sample from a rheumatoid arthritis, juvenile arthritis, or osteoarthritis patient treated with said drug antibody simultaneously with a mixture comprising 0.5 ?g/ml to 10 ?g/ml of a 1:1 conjugate of said drug antibody to a first member of a binding pair via a single lysine residue as a capture drug antibody and 0.5 ?g/ml to 10 ?g/ml of a 1:1 conjugate of said drug antibody to a detectable label via a single lysine residue as a tracer drug antibody for 0.5 to 24 hours to generate a capture drug antibody/anti-drug antibody/tracer drug antibody complex, wherein the sample comprises 1% to 20% serum and is supplemented with oligomeric human IgG prior to the incubation to a final concentration of 10 ?g/ml to 1000 ?g/ml,
(b) immobilizing the capture drug antibody/anti-drug antibody/tracer drug antibody complex formed in step (a) on a solid phase by covalently or non-covalently conjugating said first member of a binding pair to a second member of a binding pair on the solid phase,
(c) incubating the immobilized complex with an antibody against the detectable label of the tracer drug antibody, conjugated to a second detectable label, and
(d) detecting the anti-drug antibodies against said drug antibody via a signal of the detectable label of the antibody of step (c), and
wherein the drug antibody is an anti-inflammatory antibody.
US Pat. No. 10,166,534

METHOD FOR REDUCTION OF ORGANIC MOLECULES

RHEINISCH-WESTFALISCHE TE...

10. The method according to claim 7, wherein the sulfonic acid is selected from the group consisting of methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, p-bromobenzosulfonic acid, p-nitrobenzosulfonic acid, sulfuric acid, hydrochloric acid, hydrofluoric acid, trifluoroacetic acid, perchloric acid, bis(trifluoromethane)sulfonimide and mixtures thereof.
US Pat. No. 10,166,281

METHOD AND COMPOSITION FOR MODULATING IMMUNE RESPONSE

VLP Therapeutics, LLC, W...

1. A method for modulating an immune response against a cancer, wherein said method comprises administering, to a subject with a cancer, an effective amount of a composition comprising an alphavirus virus like particle, wherein said alphavirus virus like particle does not contain a heterologous antigen.
US Pat. No. 10,167,306

CRYSTALLINE FORM OF 1-(BETA-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE AND PREPARATION METHOD THEREOF

SHANGHAI DESANO PHARMACEU...

1. A crystalline form W of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, wherein the crystalline form W has an X-ray powder diffraction pattern substantially as shown in FIG. 1.
US Pat. No. 10,167,307

PROCESS FOR EXTRACTION OF SAPONINS FROM AGRICULTURAL PRODUCTS

Minn-Dak Farmers Cooperat...

1. A process for extracting saponin from agricultural feedstocks, comprising:preparing an agricultural feedstock for saponin extraction from the agricultural feedstock;
introducing the prepared agricultural feedstock and water into a tank to form a feedstock water solution;
adjusting the pH of the feedstock water solution to extract a saponin solution in an extraction liquid form;
clarifying the extraction liquid form to remove any insoluble suspended solids from the saponin solution;
filtering the saponin solution with a microfiltration member to separate a clean filtrate and a concentrated saponin solution, such that a saponin level within the concentrated saponin solution is concentrated by about 2 to about 10 times as compared to the saponin level in the saponin solution;
adjusting a pH of the concentrated saponin solution through the addition of an acid such that the pH of an acidified concentrated saponin solution is within a pH range from about 2 to about 7;
centrifuging the acidified concentrated saponin solution to separate suspended saponin solids from the acidified concentrated saponin solution thereby forming a suspended solid stream and a saponin-rich centrate; and
drying the suspended solid stream to form a purified saponin product.
US Pat. No. 10,166,283

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN

1. A nucleic acid sequence comprising or coding fora) a coding region, encoding at least one peptide, wherein said peptide is not a histone peptide;
b) at least one histone stem-loop; and
c) a poly(A) sequence or polyadenylation signal;
wherein said peptide comprises a pathogen antigen or an antigenic fragment thereof, wherein the antigen is an antigen from a pathogen associated with infectious disease.
US Pat. No. 10,165,772

METHODS AND COMPOUNDS FOR INCREASING RED BLOOD CELL SURVIVAL

1. A blood or blood product storage kit comprising (a) a bag for ex vivo blood or blood product storage and (b) a conservation solution comprising from 10 ?M to 200 ?M of serotonin.
US Pat. No. 10,168,077

SELF-HEATING THERMAL INTERFACE MATERIAL

International Business Ma...

1. A self-heating thermal interface material (TIM), the self-heating TIM comprising:a TIM; andat least one heat producing component dispersed within the TIM, wherein the at least one heat producing component further comprises:at least one first microcapsule, the at least one first microcapsule having an outer shell, the outer shell forming a boundary between the TIM and contents of the at least one first microcapsule, the outer shell configured to sustain application of a compressive force without rupturing;
at least one first reactant and an at least one second reactant contained within the outer shell; and
at least one isolating structure within the outer shell, the at least one isolating structure preventing the at least one first reactant and the at least one second reactant from coming into contact when the compressive force is not applied, the at least one isolating structure configured to rupture when the compressive force is applied, the rupturing causing the at least one first reactant and the at least one second reactant to come into contact, the contact producing an exothermic reaction, the heat from the exothermic reaction transferring to the TIM.
US Pat. No. 10,166,285

RECOMBINANT VIRUS WITH DIMINISHED LATENCY AND METHODS OF USING SAME

1. A recombinant virus comprising all or a portion of a herpes virus genome, wherein a latency gene or its promoter is altered or modified so that the latency gene is overexpressed or has reduced expression, wherein the latency gene is a gene that corresponds to VZV ORF29 gene and encodes a major DNA binding protein, and wherein the virus has an impaired ability to establish latency and at least one of:the promoter is a heterologous promoter;
the latency gene is at a different location in the genome relative to its native location; or
a combination thereof.
US Pat. No. 10,168,334

IDENTIFICATION OF CANCER PROTEIN BIOMARKERS USING PROTEOMIC TECHNIQUES

Yale University, New Hav...

1. A method comprising:(a) measuring the expression level of proteins that consist essentially of prolactin, osteopontin (OPN), leptin, and at least one additional protein in a sample from a female subject, wherein the at least one additional protein is selected from macrophage migration inhibitory factor (MIF), insulin-like growth factor (IGF-II), 6Ckine, angiotensin converting enzyme (ACE), brain-derived neurotrophic factor (BDNF), E-Selectin, epidermal growth factor (EGF), eotaxin-2 (Eot-2), epidermal growth factor receptor 1 (ErbB 1), follistatin, hemofiltrate CC chemokine 4 (HCC4), herpes virus entry mediator (HVEM), insulin-like growth factor binding protein 2 (IGFBP-2), interleukin-17 (IL-17), interleukin 1 soluble receptor II (IL-1sRII), interleukin 2 soluble receptor alpha (IL-2 sR?), macrophage colony stimulating factor receptor (M-CSF R), macrophage inflammatory protein 1alpha (MIP-1?), macrophage inflammatory protein 3 beta (MIP3?), matrix Metalloproteinase-8(MMP-8), matrix metalloproteinase 7 (MMP-7), myeloid progenitor inhibitory factor 1 (MPIF-1), pulmonary and activation-regulated chemokine (PARC), platelet-derived growth factor receptor beta (PDGF R ?), protein C, tumor necrosis factor receptor 1 (TNF-RI), tumor necrosis factor alpha (TNF-?), soluble Vascular Adhesion Protein-1(sVAP-1), vascular endothelial growth factor receptor 2 (VEGF R2), VEGF receptor 3 (VEGF R3), human stratum corneum chymotryptic enzyme (HSCCE), kallikrein 4, kallikrein 5, kallikrein 6 (protease M), kallikrein 8, kallikrein 9, kallikrein 10, cancer antigen 125 (CA 125), CA15-3, CA19-9, OVX1, lysophosphatidic acid (LPA), carcinoembryonic antigen (CEA), macrophage colony-stimulating factor (M-CSF), prostasin, CA54-61, CA72, HMFG2, interleukin-6 (IL-6), interleukin-10 (IL-10), LSA, NB70K, PLAP, TAG72, TPA, UGTF, WAP four-disulfide core domain 2 (HE4), matrix metalloprotease 2, tetranectin, inhibin, mesothelin, MUC1, vascular endothelial growth factor (VEGF), NOTCH3, E2F transcription factor 3 (E2F3), GTPase activating protein (RACGAP1), hemotological and neurological expressed 1 (HN1), apolipoprotein A1, laminin, claudin 3 (CLDN3), claudin 4, tumor-associated calcium signal transducer 1 (TROP-1/Ep-CAM), tumor-associated calcium signal transducer 2 (TROP-2), ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, matriptase (TADG-15), stratifin, transforming growth factor-beta receptor III (TGF-?-RIII), platelet-derived growth factor receptor alpha, SEMACAP3, ras homology gene family member I (ARHI), thrombospondin 2, disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2), and haptoglobin-alpha subunit in the sample from the subject;
(b) comparing the expression level of each of the measured proteins to a reference sample for each of the measured proteins; and
(c) determining if there is a significant difference in the expression level of each of the measured proteins in the sample as compared to the reference sample.
US Pat. No. 10,165,774

DEFOAMER USEFUL IN A PERACID COMPOSITION WITH ANIONIC SURFACTANTS

Ecolab USA Inc., Saint P...

1. A low-foaming equilibrium peracid composition comprising:a C1-C22 peroxycarboxylic acid;
a C1-C22 carboxylic acid;
hydrogen peroxide;
a mineral acid;
an anionic surfactant; and
from about 0.6 wt-% to about 0.75 wt-% of a metal salt defoaming agent, wherein the defoaming agent is aluminum sulfate;
wherein the composition has a use solution pH below about 4;
wherein the composition is provided as a concentrate, and wherein the composition is subsequently diluted at a ratio of between about 1:100 and about 1:5,000.
US Pat. No. 10,166,286

MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME

The Board of Trustees of ...

1. A method of treating an autoimmune disease or inflammatory disease in a human subject in need thereof, the method comprising administering to the subject a mixed allergen composition comprising:2 to 20 different flours or powders, wherein at least one flour or powder is a nut flour selected from the group consisting of peanut, almond, walnut, cashew, hazelnut, pecan, and pistachio, at least one flour or powder is an animal powder selected from the group consisting of shrimp, cod, and salmon, and the mixed allergen composition comprises equal parts by protein weight of each flour or powder; and optionally
a vitamin selected from the group consisting of vitamin D and vitamin C;
wherein the composition is administered to the subject at least weekly or at least every other week.
US Pat. No. 10,167,312

METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS

RHYTHM PHARMACEUTICALS, I...

1. A method for treating obesity or a metabolic syndrome in a subject in need thereof, wherein the method comprises administering to said subject an effective amount of Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO: 140) or a pharmaceutically acceptable salt thereof, wherein the subject is a heterozygous carrier of an MC4R mutation.
US Pat. No. 10,168,337

METHOD AND BIOMARKERS FOR THE DETECTION OF DENGUE HEMORRHAGIC FEVER

THE BOARD OF REGENTS OF T...

1. A method for treating a subject having a dengue virus infection comprising:(a) measuring levels of (i) high molecular weight albumin, (ii) complement factor D and (iii) complement factor H; and determining a ratio of complement factor D to complement factor H (FactorD/FactorH) in a serum sample from the subject;
(b) measuring levels of IL2, desmoplakin, or IL2 and desmoplakin in a serum sample from the subject;
(c) determining with an accuracy of at least 90% by multivariate adaptive regression splines (MARS) classifier if the subject is at risk of developing dengue hemorrhagic fever (DHF) based on (i) the levels of high molecular weight albumin, (ii) the FactorD / FactorH ratio, and (iii) the levels of desmoplakin, or the levels of desmoplakin and IL2; and
(d) treating the subject with intensive supportive care if the subject is determined to be at risk of developing DHF.
US Pat. No. 10,166,289

COMPOSITIONS INCLUDING BETA-GLUCANS AND METHOD OF USE

Biothera, Inc., Eagan, M...

1. A method comprising:administering to a subject a first composition that comprises a yeast-derived soluble ?-glucan; and
administering to the subject a second composition that comprises a TLR agonist component, which is administered subsequent to the first composition;
wherein each of the first composition and second composition is in an amount that, in combination with the other, is effective to increase the subject's immune response to an antigen.
US Pat. No. 10,167,570

N-TYPE SIC SINGLE CRYSTAL AND METHOD FOR ITS PRODUCTION

TOYOTA JIDOSHA KABUSHIKI ...

1. A n-type SiC single crystal, which is grown on a SiC seed crystal substrate, the n-type SiC single crystal comprising germanium and nitrogen, wherein the density ratio of the germanium and the nitrogen [Ge/N] satisfies the relationship 0.24?[Ge/N]?0.83,the nitrogen density [N] satisfies the relationship 1.00×1019/cm3?[N]?1.00×1020/cm3,
the germanium density [Ge] satisfies the relationship 1.70×1018/cm3<[Ge]<1.60×1020/cm3, and the n-type SiC single crystal has a resistivity of 10 m?·cm or lower, and the same threading dislocation density level as the seed crystal substrate.
US Pat. No. 10,165,778

METHOD FOR CONTROLLING PESTS IN SOYBEAN

BASF SE, Ludwigshafen (D...

1. A method for controlling pests from the family of Pentatomidae and/or Thripidae, comprising contacting the pests, their food supply, habitat and/or breeding ground with one or more components of the ginkgo tree selected from the group consisting of bilobalide, ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and ginkgolide M.
US Pat. No. 10,166,290

INTRALESIONAL (INTRATUMORAL) DINITROCHLOROBENZENE AND ASSOCIATED COMPOUNDS COADMINISTERED WITH CHECKPOINT INHIBITORS FOR CANCER TREATMENT INCLUDING TREATMENT OF METASTATIC CUTANEOUS CANCERS

1. A method of treating a primary or recurrent cancerous nodule or nodules in a subject comprising administering an intralesional injection of compounds including dinitrohalogenated benzene in association with the use of previous, subsequent, or simultaneous administration of a checkpoint inhibitor selected from the group consisting of ipilimumab, pembrolizumab, nivolumab and tremelimumab.
US Pat. No. 10,166,803

RECORDING MEDIUM

Canon Kabushiki Kaisha, ...

1. A recording medium comprising:a substrate; and
an ink-receiving layer provided on the substrate,
wherein the ink-receiving layer comprises a silica particle and a water-insoluble resin, and
wherein the silica particle satisfies the following expressions 1 and 2 when an average pore radius thereof determined by the BJH method is taken as r (nm), and an oil absorption thereof measured by the linseed oil droplet method is taken as V (ml/100 g):
r?5.0 (nm); and  expression 1:
V/r?80 ((ml/100 g)/nm).  expression 2:
US Pat. No. 10,165,780

METHODS AND COMPOSITIONS FOR TREATING POLLUTION

Aqua Dynamic Solutions, L...

1. A water treatment puck comprising:a. an oxidative alkali in a concentration from 30 to 50 percent by weight of the puck;
b. a clarifying agent comprising a dry powdered form of an activated botanical protein obtained from drumstick tree seed material (genus Moringa) in a concentration from 5 to 20 percent by weight of the puck; and
c. a dry powdered form of a Ricinus seed extract in a concentration from 0.5 to 20 percent by weight of the puck,
wherein the puck is a compressed homogenous mixture.
US Pat. No. 10,166,292

BLOCKING IL-9 SIGNALING IN CONJUNCTION WITH CHEMOTHERAPY TO TREAT CANCER

Mayo Foundation for Medic...

1. A method for treating a mammal having colon or breast cancer, wherein said method comprises administering a therapeutically effective amount of an inhibitor of IL-9 signaling alone to said mammal, wherein said inhibitor is an anti-IL-9 antibody, and wherein the progression of said colon or breast cancer or the number of colon or breast cancer cells within said mammal is reduced.
US Pat. No. 10,168,598

METHOD FOR SCANNING ALONG A CONTINUOUS SCANNING TRAJECTORY WITH A SCANNER SYSTEM

Femtonics Kft., Budapest...

1. A method for scanning along a continuous scanning trajectory with an electromagnetic beam, comprising the steps of:providing a first pair of acousto-optic deflectors comprising first and second acousto-optic deflectors for deflecting the electromagnetic beam in a x-z plane;
providing a second pair of acousto-optic deflectors comprising third and fourth acousto-optic deflectors for deflecting the electromagnetic beam in a y-z plane;
passing the electromagnetic beam through said first and second pairs of acousto-optic deflectors while providing time dependent acoustic frequency chirps wherein each individual frequency chirp changes with time continuously and non-linearly in the first, second, third and fourth deflectors so as to cause a focal spot of the electromagnetic beam to move continuously along the scanning trajectory.
US Pat. No. 10,165,781

COMPOSITIONS AND METHODS USEFUL FOR THE PREVENTION OF MALARIA AND DENGUE VIRUS TRANSMISSION

The Johns Hopkins Univers...

1. A method for controlling malaria and dengue virus transmission via mosquitoes comprising applying in an area where the mosquitoes are to be controlled a composition comprising mosquito nectar feed and Chromobacterium sp_Panamam (Csp_P).
US Pat. No. 10,167,321

CYTOMEGALOVIRUS ANTIGENS AND USES THEREOF

GLAXOSMITHKLINE BIOLOGICA...

1. A recombinant Human Cytomegalovirus (HCMV) gL protein, or a complex-forming fragment thereof, wherein said gL protein or fragment comprises a mutation at Protease Recognition Site residues 91-102 numbered according to SEQ ID NO: 1, wherein said mutation reduces protease cleavage at said Protease Recognition Site as compared to a control.
US Pat. No. 10,166,297

ISOLATION OF NOVEL AAV'S AND USES THEREOF

University of Massachuset...

1. A method for delivering a transgene to a target tissue in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV) that transduces cells of the target tissue and a transgene, wherein the transgene is engineered to express an RNA transcript that comprises at least one binding site for a miRNA that is expressed in cells of an off-target tissue of the subject, wherein the at least one miRNA binding site is positioned in the 5?UTR or 3?UTR of the RNA transcript, wherein the transgene comprises a tissue-specific promoter selected from a thyroxin binding globulin (TBG) promoter, insulin promoter, glucagon promoter, somatostatin promoter, pancreatic polypeptide (PPY) promoter, synapsin-1 (Syn) promoter, creatine kinase (MCK) promoter, mammalian desmin (DES) promoter, ?-myosin heavy chain (?-MHC) promoter, and a cardiac Troponin T (cTnT) promoter, and wherein the rAAV comprises a capsid protein from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV11, or AAV12.
US Pat. No. 10,167,323

NUCLEIC ACID MOLECULES ENCODING INSECTICIDAL PROTEINS

Syngenta Participations A...

1. A nucleic acid molecule comprising a nucleotide sequence that encodes an engineered Cry1Ba (eCry1Ba) insecticidal protein comprising a mutation at a position corresponding to amino acids 2 and 150; or amino acids 2, 150 and 178; or amino acids 2, 150 and 189; or amino acids 2, 150 and 199, of SEQ ID NO: 5, wherein the amino acid corresponding to position 2 is any amino acid and (a) the amino acid corresponding to position 150 is Lys; or (b) the amino acid corresponding to position 150 is Lys and the amino acid corresponding to position 178 is Ser; or (c) the amino acid corresponding to position 150 is Lys and the amino acid corresponding to position 189 is Ser; or (d) the amino acid corresponding to position 150 is Lys and the amino acid corresponding to position 199 is Lys, and wherein said protein has improved solubility or insecticidal activity against at least European corn borer (Ostrinia nubilalis) when compared to a native or wild-type Cry1Ba protein, and wherein optionally the nucleotide sequence is optimized for expression in a transgenic host cell.
US Pat. No. 10,167,324

PESTICIDAL GENES AND METHODS OF USE

AgBiome, Inc., Research ...

1. A recombinant polypeptide, comprising(a) a polypeptide comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 244, wherein said polypeptide of (a) has pesticidal activity and further comprises a heterologous amino acid sequence chemically linked to said polypeptide of (a); or,
(b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 244, wherein said polypeptide of (b) further comprises a heterologous amino acid sequence chemically linked to said polypeptide of (b).
US Pat. No. 10,165,788

METHODS AND COMPOSITIONS FOR IMPROVED DIGESTION OF MILK OLIGOSACCHARIDES

THE REGENTS OF THE UNIVER...

1. A method for promoting growth of beneficial gut bacteria in an individual having fucosylated oligosaccharides in the gut, comprising administering to the individual a composition comprising the beneficial gut bacteria, wherein the beneficial gut bacteria express a GH-29 family alpha-fucosidase and a GH-95 family alpha-fucosidase, wherein the beneficial gut bacteria are selected from B. adolescentis, B. catenulatum, B. pseudocatenulatum, B. dentium, and B. breve, thereby promoting growth of beneficial gut bacteria in the individual.
US Pat. No. 10,167,327

THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES

BRISTOL-MYERS SQUIBB COMP...

1. A method of decreasing or inhibiting fibrosis in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising a polypeptide having at least 96% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202.
US Pat. No. 10,166,303

RADIO-IMAGING AND RADIO-THERAPY OF CANCER USING ANTIBODIES TO HAAH

Panacea Pharmaceutical In...

1. A method for killing cancer cells, comprising the steps of:conjugating a radioisotope to a PAN-622 antibody, an antibody which binds to human aspartyl (asparaginyl) ß-hydroxylase (HAAH), to form a radiolabeled PAN-622 antibody and
contacting cancer cells with the radiolabeled PAN-622 antibody in an amount sufficient to kill the cancer cells, wherein the radiolabeled PAN-622 antibody binds to HAAH, thereby killing the cancer cells.
US Pat. No. 10,166,304

ANTIBODY FRAGMENTS FOR DETECTING CANCER AND METHODS OF USE

Regents of the University...

1. An immune reagent comprising a first scFv antibody fragment that specifically binds to membrane protein HSPG2 (Perlecan), wherein the first scFv antibody fragment is Clone-6 (SEQ ID NO:2).
US Pat. No. 10,167,329

STABILIZED INSULIN-LIKE GROWTH FACTOR POLYPEPTIDES

Novartis AG, Basel (CH)

1. A polypeptide comprising a human IGF-1 protein variant of SEQ ID NO: 1 wherein the amino acid glycine at position 42 is mutated to serine.
US Pat. No. 10,168,611

MASK WITH MULTILAYER STRUCTURE AND MANUFACTURING METHOD BY USING THE SAME

TAIWAN SEMICONDUCTOR MANU...

1. A structure, comprising:a first layer;
a second layer disposed over the first layer;
a third layer disposed over the second layer; and
a fourth layer disposed over the third layer;
wherein:
the first layer, the second layer, the third layer, and the fourth layer are layers of a reflective structure of a lithography mask;
the first layer and the second layer combined have a first thickness;
the third layer and the fourth layer combined have a second thickness that is different from the first thickness;
the first layer and the third layer have a first material composition; and
the second layer and the fourth layer have a second material composition different from the first material composition.
US Pat. No. 10,168,613

MASK BLANK SUBSTRATE, MASK BLANK, TRANSFER MASK, AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

HOYA CORPORATION, Shinju...

1. A mask blank substrate for use in manufacturing a mask blank provided with a thin film for forming a transfer pattern on one of a pair of opposing principal surfaces of a transparent substrate,wherein the principal surface to which the thin film is provided has a surface shape of which, in a case where a shape fitting on a virtual reference surface is carried out and difference data between the principal surface and the virtual reference surface is obtained in a calculation region within an inner side of a circle of 90 mm diameter based on a center of a substrate, a difference between a maximum height and a minimum height within the calculation region of the difference data is ?/10 or less, provided that an exposure wavelength used for transfer is ?, and
wherein the virtual reference surface has a shape defined by a Zernike polynomial expressed by a polar coordinate system, and includes one or more terms in which an order of a variable related to a radius is a second order.
US Pat. No. 10,167,334

TREATMENT OF CANCER USING ANTI-TGF-BETA AND PD-1 ANTIBODIES

XOMA TECHNOLOGY LTD., Be...

1. A method for treating cancer or reducing the recurrence of cancer comprising administering to a subject having cancer or who has had cancer, in therapeutically effective amounts, an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of Programmed cell death protein 1 (PD-1), wherein the PD-1 inhibitor is an anti-PD-1 antibody; andwherein the TGF? inhibitor is an antibody that binds TGF? comprising:
a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO: 19;
b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO: 20;
c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO: 21;
d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 22;
e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 23; and
f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 24.
US Pat. No. 10,167,335

IL-1? NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES

Agency for Science, Techn...

1. An isolated IL-1? specific antigen binding protein comprising one or more binding units selected from the group consisting of the following binding units:(i) a binding unit LI comprising Kabat residues 24-33 of SEQ ID NO: 17;
(ii) a binding unit L2 comprising Kabat residues 49-55 of SEQ ID NO: 17;
(iii) a binding unit L3 comprising Kabat residues 88-96 of SEQ ID NO: 17, or a variant thereof which contains up to five conservative amino acid substitutions in the binding unit L3;
(iv) a binding unit HI comprising Kabat residues 31-35 of SEQ ID NO: 14;
(v) a binding unit H2 comprising Kabat residues 50-65 of SEQ ID NO: 14; and
(vi) a binding unit H3 comprising Kabat residues 98-108 of SEQ ID NO: 14.
US Pat. No. 10,167,336

METHODS AND MATERIALS FOR TREATING CANCER

Mayo Foundation for Medic...

1. A method for exerting anti-cancer effects in a mammal having cancer, wherein said method comprises:(a) identifying said mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells within a T cell-containing sample; relative to a reference level of PD-1+/CD11ahigh CD8 T cells in mammals without cancer; and
(b) administering a PD-1 inhibitor to said mammal under conditions wherein naturally occurring tumor-reactive CD8 CTLs within a PD-1+/CD11ahigh CD8 T cell population of said mammal exert said anti-cancer effects against said cancer.
US Pat. No. 10,167,592

COMPOSITION FOR FIBER ADHESION AND FABRICS USING THE SAME

DOMAC LLC., Sejong (KR)

5. An article comprising a fabric manufactured by weaving a coated yarn comprising a yarn selected from polyolefin fiber, polyester fiber, nylon fiber, polyvinyl chloride fiber, polyurethane fiber, glass fiber or carbon fiber; and a coating layer, which comprises a fiber adhesion composition, the fiber adhesion composition comprising a thermoplastic resin, a titanium dioxide, a flame retardant, an ultraviolet absorber, and a heat stabilizer, wherein the fabric has a solar reflectance of 70% or more, a visible light reflectance of 80% or more, a solar transmittance of 15% or less, a visible light transmittance of 10% or less and a UV transmittance of 5% or less, wherein the article is a blind or light-shielding film.
US Pat. No. 10,167,338

METHOD OF TREATING CANCER USING IL2R BETA/COMMON GAMMA CHAIN ANTIBODIES

AGENCY FOR SCIENCE, TECHN...


US Pat. No. 10,166,314

REGENERATIVE PROSTHESES AS ALTERNATIVES TO DONOR CORNEAS FOR TRANSPLANTATION

UAB Ferentis, Vilnius (L...

1. A corneal implant having a first surface and a second surface, the corneal implant comprising:a matrix part containing a matrix material including a hydrogel of at least one first polymer and at least one second polymer, the first polymer including collagen or collagen mimetic peptide (CMP) provided with methacrylate or acrylate functional groups, the second polymer including a synthetic or a natural polymer having functional groups selected from thiol, acrylate or methacrylate, and the first and second polymers are cross-linked via said functional groups; and
a core part in a central part of the matrix material, the core part including a core material of an interpenetrating network (IPN), the IPN including polymerized olefinic monomers, UV polymerizable monomers or a mixture thereof and the hydrogel of the matrix material, the core material exposed at the first surface and at the second surface, the core part being transparent such that the core part has a light transmission of at least 80% within a wavelength range of 400 nm to 700 nm, the core part being anti-fouling, the core part configured to block or hinder cell migration and vessel ingrowth.
US Pat. No. 10,167,342

PRODUCTION OF HERSINTUZUMAB: A NEW HUMANIZED ANTIBODY AGAINST HER2 FOR CANCER TREATMENT

1. A humanized monoclonal anti-HER2 antibody for treating cancer, comprising:CDR-H1 comprising amino acid residues of 31-35 of SEQ ID NO: 1;
CDR-H2 comprising amino acid residues of 50-65 of SEQ ID NO: 1;
CDR-H3 comprising amino acid residues of 98-105 of SEQ ID NO: 1;
CDR-L1 comprising amino acid residues of 24-34 of SEQ ID NO: 5;
CDR-L2 comprising amino acid residues of 50-56 of SEQ ID NO: 5; and
CDR-L3 comprising amino acid residues of 89-97 of SEQ ID NO: 5.
US Pat. No. 10,167,343

ANTIBODIES AGAINST CD73

BRISTOL-MYERS SQUIBB COMP...

1. An isolated nucleic acid molecule encoding the heavy and light chains of an antibody which binds to human CD73, wherein the heavy and light chains respectively comprise:(a) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 5, 6, and 7, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 9, 10, and 11, respectively;
(b) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 5, 6, and 7, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 13, 14, and 15, respectively;
(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 21, 22, and 23, respectively;
(d) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 25, 26, and 27, respectively;
(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 29, 30, and 31, respectively;
(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 33, 34, and 35, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 37, 38, and 39, respectively;
(g) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 41, 42, and 43, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 46, and 47, respectively;
(h) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 41, 42, and 43, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 49, 50, and 51, respectively;
(i) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 53, 54, and 55, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 57, 58, and 59, respectively;
(j) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 61, 62, and 63, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 66, and 67, respectively;
(k) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 69, 70, and 71, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 73, 74, and 75, respectively;
(l) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 69, 70, and 71, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 77, 78, and 79, respectively;
(m) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 81, 82, and 83, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 85, 86, and 87, respectively; or
(n) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 89, 90, and 91, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 93, 94, and 95, respectively.
US Pat. No. 10,167,344

MICE EXPRESSING A LIMITED IMMUNOGLOBULIN LIGHT CHAIN REPERTOIRE

Regeneron Pharmaceuticals...

1. A method for making an antibody comprising:expressing in a single cell:
(a) a first nucleic acid sequence that encodes a first immunoglobulin heavy chain, the first nucleic acid sequence comprising a first human immunoglobulin heavy chain variable region sequence operably linked to a human immunoglobulin heavy chain constant region sequence, wherein the first human immunoglobulin heavy chain variable region sequence is identified from a B cell of a first mouse, and wherein the first mouse has been immunized with a first antigen of interest including a first epitope, and the first mouse comprises in its germline genome:
(i) exactly two unrearranged human immunoglobulin V? gene segments and five unrearranged human immunoglobulin J? gene segments operably linked to a mouse immunoglobulin light chain constant region sequence at the endogenous kappa light chain loci of the mouse, wherein the two unrearranged human immunoglobulin V? gene segments are a human V?1-39 gene segment and a human V?3-20 gene segment; and
(ii) one or more unrearranged human immunoglobulin VH gene segments, one or more unrearranged human immunoglobulin DH gene segments, and one or more unrearranged human immunoglobulin JH gene segments operably linked to a mouse immunoglobulin heavy chain constant region sequence at the endogenous heavy chain loci of the mouse;
wherein the unrearranged human heavy chain and kappa light chain immunoglobulin gene segments of the first mouse are capable of rearranging and encoding human immunoglobulin variable domains of an antibody, wherein the first mouse does not comprise an endogenous immunoglobulin V? gene segment that is capable of rearranging to form an immunoglobulin light chain variable region sequence, and wherein the first human immunoglobulin heavy chain variable region sequence encodes a first human immunoglobulin heavy chain variable domain that recognizes the first epitope; and
(b) a second nucleic acid sequence that encodes an immunoglobulin light chain, the second nucleic acid sequence comprising a human immunoglobulin kappa light chain variable region sequence fused with a human immunoglobulin light chain constant region sequence, wherein the human immunoglobulin kappa light chain variable region sequence comprises a human V?1-39 gene segment, a human V?3-20 gene segment, or a somatically hypermutated version thereof;
maintaining the cell under conditions sufficient to express a fully human antibody; and
isolating the antibody.
US Pat. No. 10,167,345

ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS

1. A nucleic acid molecule encoding for an antigen binding format comprising:a first fusion protein wherein a CH1 constant domain of an antibody is fused i) by its N-terminal end to a C-terminal end of a first single domain antibody and ii) by its C-terminal end to an N-terminal end of a second single domain antibody, wherein the C-terminal end of the CH1 constant domain includes DKT which is fused directly to the N-terminal end of the second single domain antibody, and
a second fusion protein wherein a CL constant domain of an antibody is fused by its N-terminal end to a C-terminal end of a third single domain antibody, wherein said first, second and third single domain antibody may be the same or different, and wherein said CH1 constant domain and said CL constant domain are linked via a disulfide bond.
US Pat. No. 10,167,346

COMPOSITIONS AND METHODS FOR MAKING ALPHA-(1,2)-BRANCHED ALPHA-(1,6) OLIGODEXTRANS

1. A composition comprising an alpha-(1,2)-branched alpha-(1,6) oligodextran having alpha-(1,2)-osidic side chains, wherein said oligodextran comprises a backbone comprising alpha-D-glucopyranosyl units linked by alpha-(1,6)-linkages, wherein said alpha-(1,2)-osidic side chains are randomly distributed over the backbone, wherein said backbone has an average molecular weight between about 0.5 kDa and 40 kDa, wherein said backbone comprises at least 90% alpha-(1,6)-D-glucopyranosidic linkages; whereby the composition is useful for improving the health of a subject.
US Pat. No. 10,167,347

CARBOXYLATE ESTER OF POLYSACCHARIDE

BASF SE, Ludwigshafen (D...

1. A carboxylate ester of polysaccharide, wherein the polysaccharide is esterified with trimellitic anhydride and wherein a degree of substitution of the polysaccharide lies in the range of from 1 to 2.5.
US Pat. No. 10,168,630

TONER FOR DEVELOPING ELECTROSTATIC IMAGES

KONICA MINOLTA, INC., To...

1. A toner for developing electrostatic images, comprising toner particles containing an external additive on surfaces of toner matrix particles,wherein the external additive contains at least a lanthanum-containing titanate compound.
US Pat. No. 10,167,353

METHODS FOR INCREASING POLYMER PRODUCTION RATES WITH HALOGENATED HYDROCARBON COMPOUNDS

Chevron Phillips Chemical...

1. A process for producing an ethylene polymer at a target productivity, the process comprising:(a) contacting a metallocene-based catalyst system with ethylene and an optional ?-olefin comonomer in a polymerization reactor system under polymerization conditions; and
(b) controlling an amount of a halogenated hydrocarbon compound introduced into the polymerization reactor system to produce the ethylene polymer at the target productivity;
wherein the metallocene-based catalyst system comprises at least one metallocene compound.
US Pat. No. 10,167,356

FLUORINATED POLYMERS COMPRISING PHOSPHONIC MOIETIES

3M Innovative Properties ...

1. A polymer derived from(a) a fluorinated monomer comprising at least one of
(i) CnF(2n+1)(CH2)zOC(?O)CR?CH2 wherein n is an integer selected from 1 to 8, z is an integer selected from 1 to 20, and R is H or CH3; and
(ii) CnF(2n+1)SO2(NR?)(CH2)zOC(?O)CR?CH2 wherein n is an integer selected from 1 to 8; z is an integer selected from 3 to 20, and R is H or CH3 and R? is H or C1-C8 alkyl group, wherein the fluorinated monomer is selected from a group consisting of CF3CF2CF2CH2—O—C(?O)C(CH3)?CH2; and C8F17CH2CH2OC(?O)CH?CH2” after “alkyl group”; and
(b) a monomer comprising a phosphonic moiety, wherein the phosphonic moiety is selected from a group consisting of: —CH2?CHPO3H2, CH2?CHCH2PO3H2, and CH2?CHC(?O)O(CH2)2PO3H2.
US Pat. No. 10,167,870

CAN FOR MAGNETICALLY COUPLED PUMPS AND PRODUCTION PROCESS

1. A method for manufacturing a separating can (1), said method comprising the steps of:forming a flange part (4) of the can (1);
forming a bottom (2) of the can (1);
forming a side wall (3) arrangeable in a gap between a driver and a rotor of a magnetically coupled pump in a mounted condition of the can at least partially from a material comprising a nickel constituent, with the side wall (3) being brought by a reshaping step into a target geometry, said side wall having a reshaping degree of at least 10 percent, said side wall consisting at least partially of a material containing a nickel constituent, wherein the material is a nickel-chromium-iron alloy material in a solution annealed condition comprising between 50 and 55 percent by weight of nickel, between 17 and 21 percent by weight of chromium, between 10 and 25 percent by weight of iron, and between 0.5 and 10 percent by weight of niobium; further wherein said material has a deformation-free hardenability property; and
performing a hardening of said can after reshaping by a heat treatment; wherein said reshaping is a cold forming procedure and precipitation hardening is performed after cold forming.
US Pat. No. 10,165,823

DAMPING ELEMENT IN SHOE SOLES

BASF SE, Ludwigshafen (D...

1. A process for producing a shoe sole, the shoe sole comprising a hybrid material which comprises a polyurethane foam as a matrix material and an inlay component of expanded particles of a thermoplastic polyurethane;wherein the shoe sole does not comprise foamed particles of thermoplastic polyurethane in a region of at least 0.2 cm from an exterior edge of the shoe sole;
the process comprising:
preparing an inlay form by joining the expanded particles of a thermoplastic polyurethane in an amount and size of the desired inlay by placing them into a mould of the desired inlay size and joining them within the mould to obtain a prepared inlay form or by joining them in larger amounts to form large aggregates or sheets which are then cut to inlays of the desired size to obtain a prepared inlay form;
preparing the shoe sole by placing the prepared inlay form in a shoe sole mold such that an edge of the inlay form is 0.2 cm or more from an edge of the shoe sole mold;
embedding the inlay form within a reaction mixture in the shoe sole mold; and
reacting the reaction mixture to form the matrix in the shoe sole mold; obtain the shoe sole, and
removing the matrix with embedded inlay from the mold to obtain the shoe sole;
wherein the expanded particles of the inlay component are bonded with adhesives or with thermal adhesive bonding, and the reaction mixture comprises: a polyisocyanate; a compound having a hydrogen atom reactive toward isocyanate, and optionally at least one of a chain extender, a crosslinking agent, a catalyst, a blowing agent, and a further additive.
US Pat. No. 10,167,360

PROCESS TO PRODUCE POLYOLEFIN IONOMERS AND IONOMERS PRODUCED THEREBY

Dow Global Technologies L...

1. A process to produce an ionomer comprising:reacting alkyl-cis-cyclooctene and cis-cyclooctene in a mole ratio from 1:0.05 to 0.05:1, in the presence of a difunctional acid chain transfer agent under ring opening metathesis polymerization conditions to form an unsaturated polyolefin reactive telechelic pre-polymer;
hydrogenating the unsaturated polyolefin reactive telechelic pre-polymer to produce a hydrogenated polyolefin reactive telechelic pre-polymer;
reacting the hydrogenated polyolefin reactive telechelic pre-polymer with at least one compound according to the formula aMx+b(R)y, wherein M is a metal, x is a charge of M, R is an alkyl, aryl, oxide, or fatty acid, y is a charge of R, a and b are integers of at least 1, and ax+by=0, to form an ionomer.
US Pat. No. 10,167,361

PRODUCTION OF AROMATICS AND C2+OLEFINS

ExxonMobil Chemical Paten...

1. A process for producing aromatics and C2+ olefins, the process comprising:(a) providing a feed comprising syngas;
(b) reacting at least a portion of the syngas to produce an alcohol-containing mixture comprising C2+ alcohols and ?2 wt. % of methanol, wherein the C2+ alcohols include at least ethanol and propanol and wherein the alcohol-containing mixture comprises ?15 wt. % of ethanol, the weight percentages being based on the weight of the alcohol-containing mixture;
(c) separating a first stream and a second stream from the alcohol-containing mixture, wherein (i) the first stream comprises ?90.0 wt. % of the alcohol-containing mixture's methanol, based on the weight of the alcohol-containing mixture's methanol, (ii) the second stream comprises ?90.0 wt. % of the alcohol-containing mixture's C2+ alcohols, based on the weight of the alcohol-containing mixture's C2+ alcohols, and (iii) the second stream has a propanol:ethanol weight ratio in the range of from 0.1 to 0.5;
(d) reacting at least part of the first stream's methanol to produce a first hydrocarbon and a first oxygenate, the first hydrocarbon comprising ?25.0 wt. % of aromatics, ?1.0 wt. % of propylene, and ?50.0 wt. % of saturated hydrocarbons, the weight percentages being based on the weight of the first hydrocarbon; and
(e) reacting at least part of the second stream's C2+ alcohols to produce a second product comprising a second hydrocarbon and a second oxygenate, wherein (i) the second hydrocarbon comprises C2+ olefins, (ii) the second product comprises ?20.0 wt. % ethylene, based on the weight of the second product, (iii) the second hydrocarbon has a propylene: ethylene ratio in the range of from 0.30 to 0.40, and (iv) the reacting of the at least part of the second stream's C2+ alcohol comprises an oxygenate to olefin reaction.
US Pat. No. 10,167,364

PROCESS FOR PREPARING POLYCARBONATES BY TRANSESTERIFYING DITHIOCARBONATES OR SELENIUM ANALOGUES THEREOF WITH BISPHENOLS

COVESTRO DEUTSCHLAND AG, ...

1. A process for preparing polycarbonates, comprising reacting bisphenols with a transesterifying reagent in the presence of a catalyst, wherein the transesterifying reagent comprises a compound of the general formula (I):R—X—C(O)—X?—R?  (I)
wherein
X and X? are each independently S or Se, and
R and R? are each independently alkyl or aryl or
R and R? together are an alkylene chain.
US Pat. No. 10,167,367

POLYCARBONATE BASED PI-PI STABILIZED NANO-OBJECTS AND HYDROGELS

International Business Ma...

2. An amphiphilic block copolymer comprising:a poly(ethylene glycol) (PEG) block;
a first hydrophobic polycarbonate (PC) block bonded to the PEG block, the first hydrophobic PC block including pendant aryl substituents;
a second hydrophobic PC block bonded to the first hydrophobic PC block, the second hydrophobic PC block including pendant fluoroaryl substituents;
a third hydrophobic PC block bonded to the PEG block, the third hydrophobic PC block including the pendant aryl substituents; and
a fourth hydrophobic PC block bonded to the third hydrophobic PC block, the fourth hydrophobic PC block including the pendant fluoroaryl substituents.
US Pat. No. 10,166,088

UNIFIED THREE DIMENSIONAL VIRTUAL CRANIOFACIAL AND DENTITION MODEL AND USES THEREOF

Ora Metrix, Inc., Richar...

1. A method of registering an upper arch and a lower arch of a patient, with accompanying teeth with or without roots, with respect to jaw bones or facial tissue structure, comprising the steps of:capturing a three dimensional volumetric scan of a craniofacial complex and a dentofacial complex of the patient;
defining reference planes; and
registering (1) the three dimensional volumetric scan of the dentofacial complex with accompanying roots and (2) the patient's facial structure to the defined reference planes.
US Pat. No. 10,167,369

LIGHTFAST POLYURETHANE PREPREGS AND FIBER COMPOSITE ELEMENTS PRODUCED THEREFROM

Covestro Deutschland AG, ...

1. A prepreg consisting of a fiber layer saturated with polyurethane (matrix material) that has not been fully hardened and that has an NCO value of from 3% by weight to 17% by weight (DIN EN ISO 14896:2009-07-method A: method A=NCO value determined by titration), and that has a Tg-value below 40° C. (glass transition temperature Tg measured in accordance with DIN EN ISO 53765-A-20), wherein the polyurethane is a reaction product of a reaction mixture of:an isocyanate component consisting of:
A) one or more organic isocyanates selected from the group consisting of: unblocked aliphatic or cycloaliphatic di- and polyisocyanates, isocyanurates of unblocked aliphatic or cycloaliphatic di- and polyisocyanates, and combinations of any thereof;
and a polyol formulation consisting of:
B) a polyol component made of one or more polyols with a number-average OH number of from 30 to 1000 mg KOH/g, with a number-average functionality of from 1.9 to 2.5;
C) one or more dianhydrohexitols;
D) one or more latent catalysts which are catalytically active at temperatures of from 50° to 100° C.; and
E) optionally auxiliaries and/or additives, wherein component E) excludes polyepoxides,
wherein the initial viscosity directly measured after mixing of the reaction mixture at 40° C. is from 2300 to 3200 mPas (measured in accordance with DIN EN ISO 53019), and the ratio of the number of the NCO groups in component A) to the number of the OH groups in components B) and C) is from 1.3:1 to 10:1.
US Pat. No. 10,167,371

MEDICAL DEVICES HAVING ACTIVATED SURFACES

Covidien LP, Mansfield, ...

1. A polymeric medical device having an acid or base-treated surface that is functionalized with one or more click reactive members to provide an activated surface on the polymeric medical device.
US Pat. No. 10,170,704

ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY INCLUDING THE SAME

SAMSUNG DISPLAY CO., LTD....

1. An organic electroluminescent device, comprising:a first electrode;
a hole transport region on the first electrode;
an emission layer on the hole transport region;
an electron transport region on the emission layer; and
a second electrode on the electron transport region,
wherein:
the electron transport region includes a first electron transport layer on the emission layer, and a second electron transport layer on the first electron transport layer,
an absolute value of difference between a highest occupied molecular orbital (HOMO) energy level of the emission layer and a HOMO energy level of the first electron transport layer is about 0.3 eV to about 1.5 eV,
the first electron transport layer includes a first electron transport material and a first n-type dopant, and
the second electron transport layer includes a second electron transport material and a second n-type dopant.